@Beactica profile picture
Beactica Therapeutics @Beactica

Beactica is a drug discovery company, utilising its proprietary methodologies to evaluate the interaction of molecules in order to generate novel therapeutics.

Joined December 2011
  • Tweets 98
  • Following 23
  • Followers 120
33 Photos and videos
Beactica's Head of Chemistry, Peter Brandt, to present the YAP-TEAD targeted degrader programme at the Discovery Europe 2024 conference in Basel, Switzerland, on May 23.#oncology #HippoPathway #drugdevelopment #targetedproteindegradation #tpd
1
98
Peter Brandt presenting late-breaking research poster “Degraders of TEAD based on interface 3 binders” at the AACR Annual Meeting in San Diego. Results were well received and further evidence we're on the right track! Many thanks to our collaborators at @ncats_nih_gov. #AACR24
81
We are delighted to welcome Jarl Ulf Jungnelius M.D. to the Board of Directors. #oncology #therapeutics #leadership Full story here: beactica.com/press/beactica-…
118
Beactica's Head of Chemistry, Peter Brandt, to present breakthrough in YAP-TEAD programme at the Hippo Pathway Drug Development Summit 2023 in Boston on May 25. Full story: beactica.com/press/beactica-… #oncology #HippoPathway #drugdevelopment #targetedproteindegradation
1
226
Beactica Therapeutics' Head of Discovery, Dr Konrad Koehler, to present LSD1 programme update at the @AACR Annual Meeting in Orlando, Florida. #AACR23 #LSD1 #orphandrug #GBM. Read full story: beactica.se/press/beactica-t…
2
337
cancernetwork.com/view/fda-g…

FDA Grants Orphan Drug Designation to BEA-17 for Glioblastoma | CancerNetwork

The FDA gives orphan drug designation to BEA-17, an investigational small molecule degrader that may benefit those with a common and aggressive brain tumor.

cancernetwork.com
2
193
BEA-17 has been granted Orphan Drug Designation for the treatment of glioblastoma by the U.S. Food and Drug Administration (FDA). Read full story here: beactica.com/press/beactica-….
1
3
1,103
This week marked the first face-to-face meeting of our collaboration with @dundeeuni to develop WRN degraders to target genetically defined cancers. What a difference it makes to meet in person! Many thanks to the team at @UoDLifeSciences, @DDU_Dundee and @mrcppu for a great day.
2
8
Beactica Therapeutics' CEO @PerKallblad will be at #BioEquity Europe in Milan next week to talk to investors about leveraging synthetic lethality to tackle genetically defined cancers. #cancer #precision #therapeutics
2
Beactica's Head of Chemistry Peter Brandt is at the AACR Annual Meeting in New Orleans to scan the horizon on synthetic lethality and genetically defined cancers. #cancer #AACR22 #WRN
2
We are delighted to welcome Peter Brandt as Head of Chemistry and Christina Herder and @TedFjallman to the Board. Their extensive experiences will be very valuable as we now gear up towards new goals in our fight against cancer. Full story: beactica.se/press/beactica-t…
3
The first face-to-face Board meeting for 18 months. An exciting day focussed on strategies for making the most of recent advances in our pipeline of first-in-class cancer therapeutics. A special welcome to new board members Christina Herder and @TedFjallman from Flerie Invest.
1
Synthetic lethality’s second wind - An overview of this fast-moving field with a mention of Beactica's WRN helicase collaboration with @dundeeuni and @DDU_Dundee biocentury.com/article/63574…

Synthetic lethality’s second wind

A burst of company presentations indicate the next wave of synthetic lethality programs is gaining momentum based on promising early data, more specific co...

biocentury.com
5
Beactica Therapeutics retweeted
Cision News@CisionNews
18 Mar 2021
Invest Talks - Sektoranalys Health Care: Beactica Therapeutics validerade småmolekylära plattform möjliggör effektivutveckling av innovativa läkemedelskandidater dlvr.it/RvscxP

Invest Talks - Sektoranalys Health Care: Beactica Therapeutics validerade småmolekylära plattform...

Med sin mångsidiga och kraftfulla plattform skräddarsyr Beactica Therapeutics innovativa

news.cision.com
1
2
unt.se/artikel/uppsalabolage…
1
Beactica Therapeutics retweeted
Nordic Life Science@NLifeScience
2 Mar 2021
"This is a landmark agreement for @Beactica" says CEO, Per Källblad nordiclifescience.org/beacti…

Beactica enters license and collaboration agreement - NLS

Beactica Therapeutics and Oscotec, a Korean drug development company, have announced a new research development and licensing agreement.

nordiclifescience.org
1
2
We are very pleased to announce this partnership with Oscotec, a company committed to building a strong clinical pipeline of targeted therapeutics in immunology and oncology. Full story at beactica.com/press/beactica-…. #breakthrough #cancer #therapeutics
1
3
4 years of hard work today culminated in @E_FitzG's successful defence of his Ph.D. at @UU_University. Many congrats Dr Ted! A special mention to @HelenaDanielson for top supervision during this industrial Ph.D. studentship! #newdrughunter #FBDD #biosensors #fragnet
1
14
Congratulations to @E_FitzG on his latest publication. The work was performed whilst doing his Ph.D. at Beactica and in collaboration with excellent scientists in Uppsala, South San Francisco and Amsterdam. #FBDD #biodesy #SciLifeLab pubs.rsc.org/en/content/arti…

Discovery of fragments inducing conformational effects in dynamic proteins using a second-harmonic...

Biophysical screening of compound libraries for the identification of ligands that interact with a protein is efficient, but does typically not reveal if (or how) ligands may interfere with its...

pubs.rsc.org
2
8
We are excited too embark on this collaboration with @dundeeuni, @DDU_Dundee and @mrcppu, institutions with impressive depths of expertise in the biological sciences beactica.se/press/beactica-t… #cancer #therapeutics #DNArepair #PROTACs
1
Load more